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Abstract
One histopathological characteristic of intracranial germinoma is abundant tumor-infiltrating
lymphocytes (TILs) showing a two-cell pattern with large undifferentiated tumor cells. The
programmed cell death 1 (PD-1)/programmed cell death 1 ligand (PD-L) axis has recently
been recognized as an anti-tumor immune system. To evaluate intratumor immune status in
intracranial germinoma, we examined expressions of PD-1 and PD-L1 (clone 28–8) and
subtypes of TILs. Expressions of PD-1 and PD-L1 were detected immunohistochemically in
25 formalin-fixed, paraffin-embedded tumor specimens from 24 patients with intracranial
germinoma consisting of 22 primary and 3 recurrent tumors. To evaluate subtypes of TILs,
quantification of lymphocytes with CD3, CD8, CD4, and Foxp3 was performed. Statistical
analyses were performed among PD-1, PD-L1 and subtypes of TILs. In 25 tumor tissue,
expressions of PD-1 in TILs and PD-L1 in tumor cells were identified in 96% (24/25) and
92% (23/25), respectively. Expression of PD-1 was associated with CD3+ TIL density.
Expression of PD-1 correlated with Foxp3+ TIL density and CD8+ TIL density, but not with
CD4+ TIL density. Furthermore, expression of PD-1 correlated strongly with Foxp3+/CD4+
ratio. Taken together, increase of PD-1+ expression is associated with accumulation of
Foxp3+ and CD8+ TILs. These findings intimate that PD-1/PD-L1 axis might shape the
immune infiltration suggesting a modulation of the immune response and subsequent tumor
growth in intracranial germinoma. Anti-PD-1 and anti-PD-L1 are potential immune therapeu-
tic strategies in intracranial germinoma.
Introduction
Central nervous system (CNS) germ cell tumors (GCTs) are common in Asia, where they
account for 8–15% of all CNS tumors of childhood, compared to 3–4% in the United States
[1–3]. Intracranial germinoma is the most common type of CNS GCT, accounting for up to
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two-thirds of all intracranial GCTs [2, 4]. Intracranial germinomas develop mostly in children,
with a strong predilection for the young adult population [1–3]. Surgery followed by radiother-
apy plus chemotherapy has achieved excellent survival outcomes for patients with intracranial
germinomas [5, 6]. In about 10–20% of patients, however, the tumor recurs 10 years after first-
line treatment [6]. Furthermore, since the majority of patients with this disease are children and
adolescents, a large irradiated volume or high radiation dose results in late adverse effects such
as growth disturbances or brain dysfunction[7]. Thus, with this highly curable disease, alterna-
tive therapeutic strategies for treating refractory tumors, preventing avoidable morbidity and
maintaining quality of life have become the main goals of current pediatric oncological efforts.
Programmed cell death 1 (PD-1) is a receptor in the CD28 family, and plays an important
role in immune tolerance and immune escape for a variety of tumor cells [8, 9]. One major
ligand of PD-1 is programmed death ligand 1 (PD-L1). The PD-1/PD-L1 axis attenuates anti-
tumor immune system as immune checkpoint [10]. The effector functions of T lymphocytes
expressing PD-1 in the tumor microenvironment could be down-regulated upon activation by
PD-L1, which is frequently expressed on tumor cells [11]. Immune checkpoint inhibitors have
recently constituted a novel class of treatment that target ligands and receptors [12].
Large tumor cells of intracranial germinoma are frequently accompanied by an abundance
of tumor-infiltrating lymphocytes (TILs), which demonstrate a characteristic histology known
as the “two-cell pattern” [13]. It is no exaggeration to say that the genesis, development and
survival of tumor cells depend on effective immune escape mechanisms. Recent research has
revealed that immune escape is a complex process that includes tissue isolation, molecular sim-
ulation and immune suppression [11, 14]. One of the major components of this system is an
immune checkpoint signal, the PD-1/PD-L1 axis [11]. However, expressions of PD-1 and
PD-L1 as well as anti-tumor immune reactions remain unclear in intracranial germinoma.
This study examined expressions of PD-1 and PD-L1 in intracranial germinoma and charac-
terized the subtypes of TILs showing surface antigens such as CD3+, CD8+, CD4+, and Foxp3+
using a quantitative evaluation method. Statistical analyses were performed to evaluate correla-
tions among expressions of PD-1/PD-L1 axis and subtypes of TILs in intracranial germinoma.
Materials and methods
Patient selection and sample collection
We evaluated formalin-fixed, paraffin-embedded (FFPE) tumor specimens from patients with
intracranial germinoma who were treated in Kyoto University Hospital between 2002 and
2016. We excluded two cases in which specimens were accompanied with large areas of necro-
sis and only small numbers of tumor cells were left. A total of 24 patients of surgically resected
intracranial germinoma consisting of 22 primary and 3 recurrent tumors were recruited for
this analysis. Among these, a pair of primary and recurrent tumors were from the same patient
experienced recurrence, who underwent surgical resection twice in our institute. Clinical and
pathological information was retrieved from the medical records and telephone interviews,
including complete medical history, physical examination, magnetic resonance imaging
(MRI) of the brain, and survival. After surgery, all patients received radiotherapy and chemo-
therapy. Three patients experienced recurrence, and one of those patients died. Demographic
data and tumor characteristics are indicated in Table 1. Progression-free survival time was
defined as the duration between initial treatment and identification of recurrence. Overall sur-
vival time was defined as the duration between initial treatment and date of death.
This retrospective study was conducted in accordance with the Declaration of Helsinki,
with approval from the ethics committee at Kyoto University Hospital. Written consent to use
stored specimens was obtained from all living patients or their legal surrogates.
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Immunohistochemistry and immunohistochemical assessment
Five-micrometer thickness of FFPE tissue sections were baked at 60˚C for 30 min, deparaffi-
nized in xylene, and rehydrated in graded concentrations of ethanol. Heat-induced antigen
retrieval was carried out in Tris-ethylenediaminetetraacetic acid buffer (pH 9.0) by micro-
waves, then endogenous peroxidase activity was quenched by incubating in 3% hydrogen
peroxide at 37˚C for 30 min. Monoclonal primary antibodies (anti-PD-1, 1/100, #329911, Bio-
legend, San Diego, CA; anti-PD-L1 [8–28], 1/100, ab205921, Abcam, Cambridge, UK; anti-
CD3, 1/200, ab16669, Abcam; anti-CD4, 1/100, ab133616, Abcam; anti-CD8, 1/100, ab17147,
Abcam; anti-Foxp3, 1/50, ab22510, Abcam; anti-OCT4, 1/100, ab181557, Abcam) were applied
at 4˚C overnight, then rewarming was performed at 37˚C for 30 min, followed by incubation

















1 15 M Initial Basal ganglia + 0.95 < 3.0 — 189
2 27 M Initial Neurohypophysial — 65 < 3.0 — 135
3 27 M Initial Pineal gland — < 0.5 < 3.0 — 153
4 21 F Initial Neurohypophysial — < 0.5 < 3.0 — 135
5 33 M Initial Pineal gland/
Neurohypophysial
+ < 0.5 1.9 — 121
6 23 M Initial Neurohypophysial — 22.42 2.6 — 91
7 10 F Initial Neurohypophysial — < 0.5 3.2 — 89
8 10 F Initial Pineal gland/
Neurohypophysial
+ < 0.5 2.2 — 105
9 13 F Initial Pineal gland/
Neurohypophysial
+ < 0.5 1.0 — 101
10 22 M Initial Pineal gland — 865.82 4.9 — 99
11 27 M Initial Pineal gland — < 0.5 1.4 — 99
12 22 M Initial Pineal gland — < 0.5 0.8 — 99
13 19 M Initial Pineal gland — 2.02 < 0.6 — 89
14 14 F Recurrent Neurohypophysial — NA NA + (276) 378
15 19 M Recurrent Basal ganglia/
Neurohypophysial
+ < 0.5 1.1 + (154) 242 (died)
16 12 F Initial Pineal gland — 754.33 1.8 + (45) 72
17 12 F Initial Pineal gland /
Neurohypophysial
+ 0.89 2.1 — 59
18 11 M Initial Basal ganglia — 5.09 1.4 — 56
19 24 M Initial Pineal gland /
Neurohypophysial
+ 17.29 0.7 — 41
20 11 M Initial Neurohypophysial — 3955.49 5.6 — 36
21 11 F Initial Neurohypophysial — 16.31 1.7 — 29
22 12 F Recurrent Pineal gland — 0.58 1.8 + (45) 72
23 19 M Initial Neurohypophysial — 635.29 0.6 — 26
24 14 M Initial Basal ganglia + 40.48 < 0.6 — 17
25 21 M Initial Pineal gland — < 0.5 < 0.6 — 3
Twenty-five consecutive intracranial germinoma patients were reviewed, including 22 primary cases and 3 recurrent cases. These included a pair of primary and
recurrent specimens from the same patient, who had received surgical treatment twice at our institute. Abbreviations: β-hCG, β-human chorionic gonadotropin; AFP,
alpha fetoprotein; NA, not applicable.  Case 16 and Case 22 represent the pair of primary and recurrent cases from the same patient, respectively.
https://doi.org/10.1371/journal.pone.0194594.t001
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with biotinylated secondary antibodies (EnVision™+ Dual Link System-HRP; Dako, Santa
Clara, CA) at 37˚C for 30 min. To observe specific antibody localization, 3,3’-diaminobenzi-
dine (DAB) (ImmPACT DAB Peroxidase Vector1; Vector Laboratories, Burlingame, CA)
was used as the substrate and hematoxylin was used as a nuclear counterstain. Human placen-
tal tissue served as a positive control for PD-1 and PD-L1 antibodies, while human tonsil tis-
sues served as positive control for CD3, CD4, CD8, and Foxp3 antibodies. For co-staining of
PD-L1 and OCT4, 2 different peroxidase substrates were used (DAB for OCT4 and VEC-
TOR1 SG [Vector laboratories, Burlingame, CA] for PD-L1) and no counterstain was per-
formed. For negative controls, slides were incubated with PBS in replacement of primary
antibodies. Sections were examined and scored by two independent observers who were
blinded to the clinicopathological background of patient samples. Sections for which evalua-
tions differed were re-evaluated simultaneously by observers using a double-headed micro-
scope and a consensus opinion was reached. All samples were stained at the same time.
Evaluation of immunohistochemical staining for PD-1 and PD-L1
expressions
PD-1 and PD-L1 expressions were evaluated by calculating total immunostaining score (TIS)
as the product of proportion score (PS) and intensity score (IS) [15]. PS represents the esti-
mated fraction of positively stained cells of tumor cells (PD-L1) or TILs (PD-1), respectively
(0, 0–5%; 1, 5–10%; 2, 10–25%; 3, 25–50%; 4,>50%). IS represents the estimated staining
intensity as compared with control cells (0, no staining; 1, weak; 2, moderate; 3, intense) (Fig
1). TIS (TIS = PS × IS) ranges from 1 to 12, with only nine possible values (0, 1, 2, 3, 4, 6, 8, 9,
and 12). Furthermore, we defined four subgroups: no expression, TIS 0; weak expression, TIS
1–4; moderate expression, TIS 6–8; and intense expression, TIS 9–12. Expressions of PD-1 and
PD-L1 were analyzed as a dichotomous covariate in further statistical analyses, comparing
high expression (TIS> 4) and low expression (TIS 4). For each sample, PD-1 expression on
TILs and PD-L1 expression on tumors were distinguished depending on the morphology of
the cells and the germinoma cell marker OCT4 expression [16]. A 5% cut-off value was applied
for PD-1 and PD-L1 positivity, as proposed for non-small cell lung cancer and testicular germ
cell tumors [17].
Quantitative valuation of TILs
Quantification of TILs was undertaken by counting immunopositive cells in serial sections
stained for lymphocyte differentiation antigens with the use of photomicrographs. CD3+,
CD4+, CD8+, and Foxp3+ TILs were evaluated: 5 tumor areas with abundant TILs in a
400× magnification (high-power fields [HPF]) were pictured with the use of cellSens Stan-
dard 1.9 (Olympus, Tokyo, Japan). Enumeration of TIL were carried out using Qupath soft-
ware, following the instruction on the official website (https://qupath.github.io/) [18]. TIL
density was calculated as the mean number of counted cell numbers divided by field area
(350 μm × 260 μm).
Statistical analysis
Spearman correlation was applied to analyze correlations between two ordinal parameters.
Unpaired Welch’s t test was used to compare group differences, as appropriate. A linear
regression model was fitted for trend analysis. A two-tailed significance level P< 0.05 was
applied. All statistical analyses were performed with Statistical Package for the Social Sciences
(SPSS) version 20.0 software (SPSS, Chicago, IL).
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Fig 1. Representative weak or intensive immunohistochemical staining for PD-1 and PD-L1 expression in intracranial germinomas. (A) Variable
intensities of PD-L1 expression in cancer cells and PD-1 in tumor-infiltrating lymphocytes were detected in intracranial germinomas. Representative
images show weak and high expressions of PD-1 and PD-L1. (B) Representative images of co-staining of PD-L1 (blue-grey) and OCT4 (brown) and single
staining of OCT4. Resected tumor tissues were immunostained with monoclonal anti-PD-1 (329911, Biolegend), anti-PD-L1 (ab210931, Abcam) and
OCT4 (ab181557, abcam). Original magnification: ×400.
https://doi.org/10.1371/journal.pone.0194594.g001
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Results
Highly frequent expressions of PD-1 and PD-L1 in intracranial
germinomas
We found prominent PD-1 and PD-L1 expressions to variable extents in primary intracranial ger-
minoma tissues. Representative immunohistochemical images for PD-1 and PD-L1 in intracranial
germinoma are shown in Fig 1. In these tissues, all markers showed membrane-accentuated
expression, also often accompanied by cytoplasmic expression. To visualize tumor cells, germi-
noma marker OCT4 was co-stained with PD-L1 in all cases [16]. In 25 tumor tissues, including all
recurrent samples, expression of PD-1 in TILs was identified in 96% (24/25) and PD-L1 in tumor
cells was identified in 92% (23/25). High expression of PD-1 (TIS> 4) in TILs and PD-L1 in
tumor cells were detected in 76% (19/25) and 88% (22/25), respectively. In addition, PD-1 expres-
sion was not related to PD-L1 expression in the current cohort (P = 0.697).
Quantifications and correlations of TIL subtypes in intracranial
germinomas
As all specimens were FFPE tissues and most were biopsy samples, TILs were impossible to quan-
tify with fluorescence-activated cell sorting techniques. Instead of classifying TILs into subgroups
using semiquantitatively evaluation criteria [19], we quantified TIL density using the mean counts
of immunopositive cells divided by area (350 μm × 260 μm, 0.091 mm2) under HPF.
Widespread TILs of variable density with perivascular and dispersed foci were identified in
intracranial germinomas. In detail, CD3+, CD4+, CD8+, and Foxp3+ TIL densities were
(3577 ± 1724)/mm2 (range: 547–7510/mm2), (1823 ± 921)/mm2 (range: 231–3651/mm2),
(1587 ± 968)/mm2 (range: 231–3360/mm2), and (344 ± 240)/mm2 (range: 9–888/mm2),
respectively. Among TIL subtypes, Foxp3+ TIL density was associated with CD3+ (R2 =
0.3693, P = 0.001), CD4+ (R2 = 0.3917, P< 0.001), and CD8+ TIL density (R2 = 0.4036,
P< 0.001), respectively. CD4+ TIL density correlated with CD8+ TIL density (R2 = 0.6588,
P< 0.001). Linear regression models are shown in Fig 2.
Associations between expression of PD-1 or PD-L1 and TIL subtype
densities
In 22 initial germinoma cases, CD3+ TIL density was significantly higher among patients with
high expression of PD-1 than in those with low expression of PD-1 (4008 ± 376.3/mm2 versus
2212 ± 523.6/mm2, t = 2.785, P = 0.018) (Fig 3A and 3B). We found higher Foxp3+ density
(416.7 ± 53.4/mm2 versus 153.5 ± 75.0/mm2, t = 2.860, P = 0.016) and higher CD8+ TIL den-
sity (1853 ± 212.9/mm2 versus 744.7 ± 214.2/mm2, t = 3.671, P = 0.002) in patients with high
expression of PD-1 than in those with low expression of PD-1 (Fig 4). However, no significant
difference in CD4+ TIL density was evident between patients with high and low expressions of
PD-1 (1949 ± 208.0/mm2 versus 1422 ± 378.7/mm2, t = 1.220, P = 0.256) (Fig 4). Furthermore,
Foxp3+/CD4+ ratio was higher in patients with high expression of PD-1 than in those with
low expression of PD-1 (0.222 ± 0.019 versus 0.105 ± 0.038, t = 2.727, P = 0.027) (Fig 4). In the
2 PD-L1 negative cases (case 3 and 8), the CD8+ TILs (1520.9/mm3 and 362.6/mm3, respec-
tively) were all smaller than the mean of CD8+ TILs (1587/mm3) in total. No correlation was
seen between PD-L1 expression in tumor cells and TIL subtypes (Table 2).
TIL subtype densities in recurrent germinomas
During follow-up of 6 months to 31.5 years, 3 patients (Cases 14–16) were refractory to treat-
ment and experienced recurrence, and Case 15 eventually died from the tumor. Moderate and
Expression of PD-1/PD-L1 axis in intracranial germinoma
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high expressions of PD-1 and PD-L1 were observed in these 3 recurrent patients. In the dead
case (Case 15), relatively high CD3+, CD4+, CD8+, and Foxp3+ TIL densities were observed
(Fig 5A). MRI showed dissemination of germinoma at the final recurrence (Fig 5B). In all
recurrent cases, high expressions of PD-1 and PD-L1 were detected. No difference of CD3+,
CD4+, CD8+, and Foxp3+ TIL densities were found between initial and recurrent germinoma
(Fig 5C).
Associations between clinicopathological parameters and PD-1, PD-L1,
expression and TIL subtype densities
We performed univariate analysis with expressions of PD-1 and PD-L1 and clinicopathologi-
cal parameters in the 22 primary cases. Detailed results are shown in Table 3. We identified
correlations between high expression of PD-1 in TILs and high serum β-hCG levels (cut-
off, 100 mIU/mL; n = 18 for β-hCG< 100 mIU/mL and n = 4 for β-hCG 100 mIU/mL;
Fig 2. Correlation between densities of different tumor-infiltrating lymphocyte subtypes. Linear regression models reveal associations between Foxp3+ and CD3+
(A: P = 0.001), Foxp3+ and CD4+ (B: P< 0.001), Fox3+ and CD8+ (C: P< 0.001), and CD4+ and CD8+ (D: P< 0.001) TIL densities.
https://doi.org/10.1371/journal.pone.0194594.g002
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P = 0.040). PD-L1 expression was stronger in patients < 18 years old (P = 0.018). No other
associations were found between other clinicopathological parameters and expressions of PD-
1 or PD-L1.
Fig 3. Expression of PD-1 correlated with total TIL density (CD3+). (A) Representative immunohistochemical
images of PD-1 and CD3 proteins show that CD3+ TIL density was higher in patients with high expression of PD-1
(Case 2) than in the patient with low expression of PD-1 (Case 18). Figures were taken from the same areas of tissue,
respectively. (B) Unpaired Welch’s t testing reveals that CD3+ TIL density was higher in primary germinoma cases
showing high expression of PD-1 (P = 0.018). Black arrow, TIL; white arrow, cancer cell. Original magnification: ×400.
https://doi.org/10.1371/journal.pone.0194594.g003
Expression of PD-1/PD-L1 axis in intracranial germinoma
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Discussion
The present study systematically investigated expressions of PD-1 and PD-L1 in intracranial
germinoma. We identified frequent expression of PD-L1 (23/25, 92%) in germinomatous
Fig 4. Correlations between PD-1 expression in lymphocytes and TIL subtype densities in primary intracranial germinoma. (A) Representative
immunohistochemical images for PD-1, CD4, CD8, and Foxp3 staining in two patients with PD-1 high expression (TIS> 4; Case 25) and PD-1 low
expression (TIS 4; Case 8). All representative photographs were taken in the same area of each tissue. Compared with Case 8, Case 25 showed higher PD-1
expression in TIL, higher CD8+TILs and Foxp3+ TILs. (B) Compared with low expression of PD-1, high expression of PD-1 correlated with higher Foxp3
+ TIL density, CD8+ TIL density, and Foxp3+/CD4+ ratio, but not CD4+ TIL density. All P values are according to the unpaired Welch’s t test.
https://doi.org/10.1371/journal.pone.0194594.g004
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components as well as frequent expression of PD-1 in TILs (24/25, 96%). Aoki et al reported
that PD-L1 was expressed on immune cell containing tumor but not on tumor cells in a study
of 7 pediatric intracranial germinomas (median age, 2 years; range: 0 months-16 years) [20].
Consistent with the current study, Fankhauser et al. reported frequent expression of PD-L1 in
testicular seminoma (73%), a kind of non-brain germ cell tumor with identical histology to
intracranial germinoma [17]. Intracranial germinoma is generally considered as the counter-
part of “seminoma” in the testis and “dysgerminoma” in the ovary, constituting the neoplastic
counterpart of the primordial germ cell, just as embryonal carcinoma is the neoplastic coun-
terpart of totipotent embryonal stem cells and teratoma the neoplastic counterpart of the
derivatives of the three embryonic germ layers [21]. However, little is known of the exact
genetic correlation between germinoma and seminoma. Cierna et al. reported similar PD-L1
expression in testicular seminoma with a frequency of 76% [22]. Frequency of PD-L1 expres-
sion in our cohort was comparable with that in other brain tumors such as glioblastoma (88.0–
100%) [14, 23], anaplastic astrocytoma (71.4%) [14] and medulloblastoma (56.3%) [8]. In
many types of non-brain tumor, frequent tumoral expression of PD-L1 was also reported with
tumors such as ovarian carcinoma (86.7%) [24], non-small cell lung cancer (53%) [25], and
colorectal cancer (36%) [26], renal cell carcinoma (32%) [27] and melanoma [28]. The
Table 2. PD-1 and PD-L1 expressions and TILs density in 25 germinoma tissues.
Case no. PD-1 expression in TIL PD-L1 expression in cancer cell TIL density (n/mm3)
CD3+ CD4+ CD8+ Foxp3+
1 +++ +++ 3984.6 1487.9 1022.0 402.2
2 +++ ++ 4725.3 2219.8 2731.9 123.1
3 + — 3736.3 2661.5 1520.9 219.8
4 +++ ++ 4382.4 1055.0 938.5 167.6
5 ++ ++ 876.9 611.0 230.8 237.4
6 +++ +++ 4235.2 2059.3 1920.9 312.1
7 +++ +++ 6683.5 3650.5 2892.3 786.8
8 + — 2925.3 1665.9 362.6 887.9
9 +++ +++ 3841.8 929.7 1076.9 261.5
10 +++ ++ 4136.3 1252.7 1589.0 808.8
11 +++ + 3650.5 1547.5 2186.8 8.8
12 +++ ++ 5149.5 2630.8 3065.9 437.4
13 ++ +++ 7509.9 2729.7 3173.6 472.5
14# +++ +++ 3925.3 2857.1 2206.6 320.9
15# +++ +++ 1896.7 1035.2 663.7 461.5
16 ++ +++ 4518.7 2648.4 2529.7 349.5
17 — +++ 546.7 408.8 270.3 24.2
18 + +++ 2578.0 1775.8 1189.0 118.7
19 +++ +++ 4325.3 3145.1 1665.9 725.3
20 + +++ 2756.0 1791.2 826.4 402.2
21 +++ +++ 2402.2 1637.4 1483.5 123.1
22 +++ +++ 3519.2 1881.3 1624.2 219.8
23 + +++ 731.9 230.8 298.9 167.6
24 +++ +++ 1189.0 703.3 852.7 237.4
25 +++ +++ 5206.6 2956.0 3360.4 312.1
 Case 16 and case 22 are a pair of initial and recurrent cases of the same patient, respectively.
# The patients experienced pre-operative radiochemotherapy and recurrence.
https://doi.org/10.1371/journal.pone.0194594.t002
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discrepancies between PD-L1 expression in germinomas among studies might be attributable
to the use of primary antibodies from different manufacturers or different immunoreactivities
between the manual operation in our study and the automated staining system used in the
study by Aoki et al. Taken together, previous investigations into the same category of pathol-
ogy and our study of 24 patients offer positive confirmation of the frequent expression of
PD-L1 in intracranial germinoma.
The histology of intracranial germinoma is characteristic, exhibiting numerous TILs
among large tumor cells, as the so-called “two-cell pattern”, suggesting a peculiar host-
immune response to the tumor. In our cohort, numerous TILs were also found in all 25 sam-
ples of intracranial germinoma tissue (Fig 2). The majority of TILs have been reported to be
T-lymphocytes. In 1979, Neuwelt and Smith reported T-lymphocyte membrane marker as
present in 51% of small cells in germinoma tissues [29]. Saito et al. also reported that 70–80%
of TILs were T lymphocytes, infiltrating either diffusely or in clusters, whereas 20–30% of
TILs were B lymphocytes that tended to cluster in tumor tissues [30]. TILs have recently
received close attention in terms of anti-tumor immune function. Since functions of immune
Fig 5. TIL subtype densities in initial and recurrent germinomas. (A) Representative immunohistochemical images
for CD3, CD4, CD8, Foxp3, PD-1, and PD-L1 in the patient (Case 15) who died from the disease (progression-free
time, 154 months; overall survival, 242 months). High CD3+, CD4+, CD8+, and Foxp3+ TIL densities were detected.
Moderate membranous PD-1 expression (TIS = 8) and intense membranous PD-L1 expression (TIS = 12) in tumor
cells were detected. Photographs were taken under high-power fields (original magnification ×400). (B) Gadolinium-
enhanced MRI shows disseminated tumor masses (black arrow). (C) Comparison of TIL subtype densities between
initial and recurrent germinoma tissues. No difference of CD3+, CD4+, CD8+, and Foxp3+ TIL densities was found
between initial and recurrent cases. All P values were calculated according to the un-paired Welch’s t test.
https://doi.org/10.1371/journal.pone.0194594.g005
Table 3. Correlation between PD-1 and PD-L1 expression and clinical parameters of 22 initial intracranial patients.
n PD1 PD-L1
TILs P value Tumor cells P value
— + ++ +++ — + ++ +++
Total 22 1 5 3 13 2 1 6 13
Age 0.308 0.018
< 18 y 10 1 3 1 5 1 0 0 9
 18 y 12 0 2 2 8 1 1 6 4
Gender 0.788 0.561
Male 15 0 4 2 9 1 1 5 8
Female 7 1 1 1 4 1 0 1 5
β-hCG (nIU/mL) 0.040 0.424
< 100 18 0 3 3 12 2 1 5 10
 100 4 1 2 0 1 0 0 1 3
AFP (ng/mL) 0.876 0.674
< 3 19 1 4 3 11 2 1 5 11
 3 3 0 1 0 2 0 0 1 2
Lesion site 0.808 0.675
Neurohypophysial 8 1 2 0 5 0 0 2 6
Pineal gland 11 0 2 3 6 2 1 4 4
Basal ganglia 3 0 1 0 2 0 0 0 3
Multifocal lesions 0.788 0.877
No 15 0 4 2 9 1 1 4 9
Yes 7 1 1 1 4 1 0 2 4
Abbreviations: βhCG, beta human chorionic gonadotropin β subunit; AFP alpha fetoprotein.
https://doi.org/10.1371/journal.pone.0194594.t003
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checkpoint signals, such as the PD-1/PD-L1 axis, were discovered in cancer, most studies have
focused on correlations between PD-1, PD-L1 and TILs using semiquantitatively analyses, but
limited studies have reported the details of infiltrating T-lymphocyte subtypes, particularly in
central nervous system tumors. Berghoff et al. reported that, in glioblastoma, PD-1+ TIL den-
sity correlated positively with CD3+ TIL density and CD8+ TIL density [23]. Our previous
study revealed that high expression of PD-L1 was associated with reduced infiltration of CD8
+ T cells and poor prognosis in medulloblastoma [8]. The current study analyzed the density
of TIL subtypes with quantified data. As a result, expression of PD-1 in TILs correlated posi-
tively with CD8+ TIL and CD3+ TIL densities. In addition, expression levels of PD-1 in TILs
did not influence CD4+ TIL density. However, the underlying mechanisms require further
research for interpretation. Interactions between immune and tumor cells play cardinal roles
during malignant progression [31]. Furthermore, dysfunction of the anti-tumor immune sys-
tem may result in the progression of germinoma to the development of symptoms.
Intracranial germinomas arise mostly in the neurohypophysis (30.1%) and pineal regions
(51%), but infrequently in the basal ganglia (3.3%), cerebellopontine angle (2.6%), lateral ven-
tricle (2%), cerebellum (2%) and multiple sites (8.5%) [32]. Germinoma cells actually show the
malignant characteristic of infiltration into brain parenchyma, especially around the subven-
tricular regions, and display recurrence at different areas and dissemination into the CSF
space. Intracranial germinomas are highly radiosensitive and potentially curable using radio-
therapy alone [33, 34]. As well documented in the literature, CNS radiation for pediatric
patients leads to dysfunctions in growth [35], the endocrine milieu [36], and neurocognition
[37]. A reduced dose of radiotherapy to the whole ventricular area with chemotherapy has
been introduced into treatment and has yielded promising therapeutic responses [6, 38, 39].
However, the side effects of radiotherapy remain inevitable, even when dose and target vol-
umes have been reduced. Meanwhile, clinical trials to substitute radiation with chemotherapy
have resulted in increased relapse rates and inferior outcomes, and chemotherapy alone is thus
currently not an acceptable treatment option [40, 41]. Despite these efforts to establish reduced
radiotherapy protocols in combination with chemotherapy, 10–20% of intracranial germino-
mas are bound to recur after first-line treatment and no standard second-line treatments have
been defined [6, 42–44]. To conquer radiation-related side effects as well as recurrent tumors,
a major task is to develop a novel therapeutic option for germinoma. Our results suggest
immune checkpoint therapy as one possible option. Antibodies targeting checkpoint mole-
cules such as PD-1 have already shown therapeutic effects on non-small cell lung cancer and
melanoma, and PD-L1 expression exhibited a positive correlation with response to PD-1 inhi-
bition in those tumors [45, 46]. Preliminary efficacy of PD-1 antibodies was reported in seven
patients with relapse of extracranial GCT after high-dose chemotherapy and stem cell trans-
plantation [47]. Three of those patients received PD-1 antibodies for at least 6 months and
long-term tumor response was achieved in two of the three patients, with tumor tissues show-
ing highly positive results for PD-L1 staining. This report encourages examination of the
efficacy of immune checkpoint therapy for intracranial germinoma. Given the existence of
blood-brain barrier (BBB), the penetrance of PD-1 antibodies into CNS via BBB is not fully
known. However, the BBB disruption in brain neoplasms could be observed with a marked
heterogeneity [48]. In addition, radiotherapy, a standard therapeutic approach in intracranial
germinomas, could further facilitate the penetrance of activated anti-tumor immune cells [49]
and possibly the access of PD-1 antibodies. Actually, many clinical trials are ongoing to explore
PD-1 in patients with primary (NCT02017717) or metastatic (NCT02320058) brain tumors.
However, planning a suitable clinical trial is difficult, because intracranial germinoma is rare,
and relapsed cases are even rarer. An international study for this context is thus desirable to
develop novel approaches to the treatment of intracranial germinoma.
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Conclusion
In the present study, expressions of PD-1 and PD-L1 were detectable in 96% (24/25) and 92%
(23/25) of germinoma tissues, respectively. PD-1 expression in lymphocytes was associated
with Foxp3+ TIL density. Increases in PD-1+ TILs was associated with accumulation of CD8
+ TILs, which might be caused by immune dysfunction. Induction of Foxp3+ TILs from CD4
+TILs causes immune tolerance. These results intimate the breakdown of the tumor immune
system that might be induced by PD-1/PD-L1 axis in intracranial germinoma, suggesting the
potential efficacy of immune checkpoint therapy.
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